PL3160498T3 - Cząsteczki na bazie IL-15 i sposoby ich zastosowania - Google Patents

Cząsteczki na bazie IL-15 i sposoby ich zastosowania

Info

Publication number: PL3160498T3
Authority: PL; Poland
Prior art keywords: methods; application; molecules based; molecules
Prior art date: 2014-06-30

Application number

PL15815782T

Other languages

English (en)

Inventor

Bai LIU

Peter Rhode

Wenxin Xu

Hing C. Wong

Original Assignee

Altor Bioscience Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-06-30

Filing date

2015-06-30

Publication date

2022-02-21

2015-06-30 Application filed by Altor Bioscience Corporation filed Critical Altor Bioscience Corporation

2022-02-21 Publication of PL3160498T3 publication Critical patent/PL3160498T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pulmonology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL15815782T 2014-06-30 2015-06-30 Cząsteczki na bazie IL-15 i sposoby ich zastosowania PL3160498T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462018899P	2014-06-30	2014-06-30
PCT/US2015/038587 WO2016004060A2 (en)	2014-06-30	2015-06-30	Il-15-based molecules and methods of use thereof
EP15815782.6A EP3160498B1 (en)	2014-06-30	2015-06-30	Il-15-based molecules and methods of use thereof

Publications (1)

Publication Number	Publication Date
PL3160498T3 true PL3160498T3 (pl)	2022-02-21

Family

ID=54929364

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15815782T PL3160498T3 (pl)	2014-06-30	2015-06-30	Cząsteczki na bazie IL-15 i sposoby ich zastosowania

Country Status (11)

Country	Link
US (17)	US9925247B2 (pl)
EP (3)	EP3160498B1 (pl)
JP (5)	JP6842926B2 (pl)
KR (4)	KR102398246B1 (pl)
CN (3)	CN112494646A (pl)
AU (4)	AU2015284248B2 (pl)
CA (2)	CA3151221A1 (pl)
ES (1)	ES2899890T3 (pl)
MX (1)	MX387159B (pl)
PL (1)	PL3160498T3 (pl)
WO (1)	WO2016004060A2 (pl)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2470772T3 (es)	2007-05-11	2014-06-24	Altor Bioscience Corporation	Moléculas de fusión y variantes de IL-15
EP3061462B1 (en)	2007-07-02	2019-02-27	Etubics Corporation	Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
CN103370339B (zh)	2010-09-21	2017-12-26	阿尔托生物科学有限公司	多聚体il‑15可溶性融合分子与其制造与使用方法
US11053299B2 (en)	2010-09-21	2021-07-06	Immunity Bio, Inc.	Superkine
WO2018112219A1 (en) *	2016-12-14	2018-06-21	Nant Holdings Ip, Llc	Superkine
WO2014031178A1 (en)	2012-08-24	2014-02-27	Etubics Corporation	Replication defective adenovirus vector in vaccination
KR102398246B1 (ko)	2014-06-30	2022-05-17	알토 바이오사이언스 코포레이션	Il-15-베이즈드 분자 및 이의 사용 방법
CN113456812B (zh)	2015-01-09	2024-08-20	埃图比克斯公司	用于联合免疫治疗的方法和组合物
WO2016112188A1 (en)	2015-01-09	2016-07-14	Etubics Corporation	Methods and compositions for ebola virus vaccination
WO2016172249A1 (en)	2015-04-20	2016-10-27	Etubics Corporation	Methods and compositions for combination immunotherapy
US11661455B2 (en)	2016-02-05	2023-05-30	Orionis Biosciences BV	Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
ES2981745T3 (es) *	2016-02-05	2024-10-10	Orionis Biosciences BV	Agentes de señalización biespecíficos y usos de los mismos
WO2017177175A1 (en) *	2016-04-07	2017-10-12	The George Washington University	Methods and compositions targeting retroviral latency
WO2017205726A1 (en)	2016-05-27	2017-11-30	Altor Bioscience Corporation	Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
MX2018014602A (es)	2016-05-27	2019-06-10	Etubics Corp	Composiciones de vacunas neoepitopos y metodos de uso de las mismas.
JP2019524692A (ja) *	2016-06-30	2019-09-05	ナントホールディングスアイピーエルエルシーＮａｎｔＨｏｌｄｉｎｇｓＩＰ，ＬＬＣ	Ｎａｎｔ癌ワクチン
KR102562519B1 (ko)	2016-10-14	2023-08-02	젠코어 인코포레이티드	IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
US20180200366A1 (en) *	2016-10-21	2018-07-19	Altor Bioscience Corporation	Multimeric il-15-based molecules
WO2018081830A1 (en) *	2016-10-31	2018-05-03	Oregon Health & Science University	Combinations of agents to treat hematological malignancies
WO2018134782A1 (en) *	2017-01-20	2018-07-26	Novartis Ag	Combination therapy for the treatment of cancer
EP3570870A1 (en) *	2017-01-20	2019-11-27	Novartis AG	Combination therapy for the treatment of cancer
US10440535B2 (en)	2017-01-25	2019-10-08	The George Washington University	System and method for asset-agnostic wireless monitoring and predictive maintenance of deployed assets
US11629340B2 (en)	2017-03-03	2023-04-18	Obsidian Therapeutics, Inc.	DHFR tunable protein regulation
US11129883B2 (en)	2017-03-06	2021-09-28	Altor BioScience, LLC.	IL-15-based fusions to IL-12 and IL-18
US20190048055A1 (en) *	2017-03-31	2019-02-14	Altor Bioscience Corporation	Alt-803 in combination with anti-cd38 antibody for cancer therapies
CN110612121A (zh) *	2017-05-11	2019-12-24	南克维斯特公司	用于脊索瘤治疗的抗-egfr/高亲和力nk组合物和方法
CN110831620A (zh) *	2017-05-26	2020-02-21	埃特彼塞斯公司	包含il-15超激动剂的联合免疫疗法
US11084863B2 (en)	2017-06-30	2021-08-10	Xencor, Inc.	Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
CN108070556A (zh) *	2017-07-26	2018-05-25	深圳市北科生物科技有限公司	用于免疫细胞培养的方法和组合物
CN109705211B (zh)	2017-10-26	2020-08-18	苏州复融生物技术有限公司	一种IgG1 Fc单体及其应用
US11767367B2 (en) *	2017-11-03	2023-09-26	Precision Biologics, Inc.	Monoclonal antibody neo-201 for the treatment of human carcinomas
US20190241665A1 (en) *	2018-01-25	2019-08-08	Wisconsin Alumni Research Foundation	Methods of inhibiting metastasis in cancer
WO2019147925A1 (en)	2018-01-26	2019-08-01	Nantcell, Inc.	Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
BR112020015202A2 (pt) *	2018-03-01	2020-12-29	Glycotope Gmbh	Construções de proteínas de fusão compreendendo um anticorpo anti-muc1 e il-15
CN111867612B (zh) *	2018-03-26	2024-11-12	阿尔托生物科学有限责任公司	抗PDL1、IL-15和TGF-β受体组合分子
US11505595B2 (en)	2018-04-18	2022-11-22	Xencor, Inc.	TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
MX2020010910A (es)	2018-04-18	2021-02-09	Xencor Inc	Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
SG11202010159RA (en) *	2018-04-18	2020-11-27	Xencor Inc	Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
US11564980B2 (en)	2018-04-23	2023-01-31	Nantcell, Inc.	Tumor treatment method with an individualized peptide vaccine
TWI787500B (zh) *	2018-04-23	2022-12-21	美商南特細胞公司	新抗原表位疫苗及免疫刺激組合物及方法
JP6630026B1 (ja) *	2018-04-27	2020-01-15	隆代大田	免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー
WO2019219891A1 (en)	2018-05-18	2019-11-21	Daiichi Sankyo Co., Ltd.	Anti-muc1 antibody-drug conjugate
US11134120B2 (en)	2018-05-18	2021-09-28	Inveniam Capital Partners, Inc.	Load balancing in blockchain environments
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
WO2020077180A1 (en)	2018-10-11	2020-04-16	Nantcell, Inc.	Treatment of immunosuppressed subjects
MA53862A (fr)	2018-10-12	2022-01-19	Xencor Inc	Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
CA3119049A1 (en) *	2018-11-09	2020-05-14	Nektar Therapeutics	Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent
CA3122333A1 (en) *	2018-12-13	2020-06-18	Jiangsu Hengrui Medicine Co., Ltd.	Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
US11618776B2 (en)	2018-12-20	2023-04-04	Xencor, Inc.	Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
AU2020206269A1 (en) *	2019-01-11	2021-08-05	Memorial Sloan Kettering Cancer Center	Multimerization of IL-15/IL-15R-alpha-Fc complexes to enhance immunotherapy
US20220218789A1 (en)	2019-05-10	2022-07-14	Nant Holdings Ip, Llc	Nogapendekin Alfa-Inbakicept For Immune Stimulant Therapies And Treatment Of Viral Infections
WO2021006876A1 (en) *	2019-07-08	2021-01-14	Nantkwest, Inc.	Ciml nk cells and methods therefor
WO2021041886A1 (en) *	2019-08-29	2021-03-04	Nantbio, Inc.	Modified n-810 and methods therefor
KR20220087441A (ko) *	2019-09-16	2022-06-24	리젠츠 오브 더 유니버시티 오브 미네소타	면역요법 화합물 및 방법
RU2753282C2 (ru) *	2019-09-19	2021-08-12	Закрытое Акционерное Общество "Биокад"	ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
TW202128757A (zh)	2019-10-11	2021-08-01	美商建南德克公司	具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
US20210188933A1 (en) *	2019-12-18	2021-06-24	Nantcell, Inc	Methods of treating pancytopenia
JP2023537475A (ja)	2020-08-03	2023-09-01	ナントセル，インコーポレーテッド	Ｉｌ－１５スーパーアゴニストに対する薬物に特異的な薬物動態アッセイ
WO2022140701A1 (en) *	2020-12-24	2022-06-30	Xencor, Inc.	Icos targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and icos antigen binding domains
CN113321736B (zh) *	2020-12-30	2024-01-09	苏州复融生物技术有限公司	一种长效化白介素15融合蛋白及其制备方法和应用
WO2022192259A1 (en) *	2021-03-09	2022-09-15	Cureimmune Therapeutics Inc.	BIFUNCTIONAL HOMODIMERIC ANTI-PD-1 AND IL-15/IL-15Rα FUSION PROTEINS AND USES THEREOF
CN113185600A (zh) *	2021-05-28	2021-07-30	苏州复融生物技术有限公司	一种新型白介素15突变体多肽的开发及其应用
EP4351320A1 (en)	2021-06-09	2024-04-17	ImmunityBio, Inc.	Methods and systems for producing a protein of interest in a plant
CN116063512B (zh) *	2022-10-13	2025-11-07	深圳市百士通科技开发有限公司	多功能重组抗体及其制备方法和应用
WO2024137136A1 (en) *	2022-12-22	2024-06-27	University Of Houston System	Inhibitors of il-15 and their use in treating or preventing sepsis, severe sepsis and septic shock
CN120916753A (zh) *	2023-03-29	2025-11-07	星锐医药(苏州)有限公司	编码治疗性多肽的核酸及包含所述核酸的脂质纳米颗粒组合物
WO2025031437A1 (zh) *	2023-08-08	2025-02-13	北京志道生物科技有限公司	白细胞介素复合体及其用途
WO2025085781A1 (en) *	2023-10-19	2025-04-24	Genentech, Inc.	Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers
WO2025201438A1 (zh) *	2024-03-28	2025-10-02	上海津曼特生物科技有限公司	一种双融合蛋白及其用途
US12272439B1 (en)	2024-05-06	2025-04-08	Immunitybio, Inc.	Distributed ledger for medicament administration tracking

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1975A (en)		1841-02-12		Manner of constructing corn-shellers
US222A (en)		1837-06-10		Truss for the retention and radical cure qe hernia
US8507A (en)		1851-11-11		petess
JPS551222Y2 (pl)	1975-10-07	1980-01-14
JPS551222U (pl)	1978-06-15	1980-01-07
JPS5841623Y2 (ja)	1980-06-19	1983-09-20	ミツミ電機株式会社	デイテント式スライドスイツチ装置
JPS5718916A (en)	1980-07-11	1982-01-30	Iseki Agricult Mach	Shaking table sorter of automatic feeding type thresher
JPS5770185A (en)	1980-10-21	1982-04-30	Kazuo Makino	Preparation of blended oil for coal liquefaction
JPS57144287A (en)	1981-03-02	1982-09-06	Toray Ind Inc	Cyclopentabenzofuran derivative
JPS5841623U (ja)	1981-09-17	1983-03-18	日産デイ−ゼル工業株式会社	リアエンジンバスにおけるエンジンル−ムの冷却及び房内熱風排出装置
JPS6152156U (pl)	1984-09-12	1986-04-08
JPS6251570U (pl)	1985-09-18	1987-03-31
JPS648039U (pl)	1987-06-29	1989-01-17
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5314995A (en)	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
US5288931A (en) *	1991-12-06	1994-02-22	Genentech, Inc.	Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
AU5098393A (en)	1992-08-14	1994-03-15	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Recombinant toxin with increased half-life
US5747654A (en)	1993-06-14	1998-05-05	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant disulfide-stabilized polypeptide fragments having binding specificity
ATE196315T1 (de)	1994-04-06	2000-09-15	Immunex Corp	Interleukin-15
JPH09512165A (ja)	1994-04-06	1997-12-09	イミュネックス・コーポレーション	インターロイキン１５
US5541087A (en)	1994-09-14	1996-07-30	Fuji Immunopharmaceuticals Corporation	Expression and export technology of proteins as immunofusins
US7008624B1 (en)	1995-02-22	2006-03-07	Immunex Corporation	Antagonists of interleukin-15
US5795966A (en)	1995-02-22	1998-08-18	Immunex Corp	Antagonists of interleukin-15
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en)	1995-09-22	1996-07-09	The Goodyear Tire & Rubber Company	High performance blend for tire treads
AU728657B2 (en)	1996-03-18	2001-01-18	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
ES2243995T3 (es)	1996-04-26	2005-12-01	Beth Israel Deaconess Medical Center, Inc.	Antagonistas de interleucina-15.
EP0971728B1 (en)	1997-02-21	2002-12-11	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Use of interleukin-15
GB9912350D0 (en) *	1999-05-26	1999-07-28	European Molecular Biology Lab Embl	Modified cytokine
WO2001056387A1 (en)	2000-02-01	2001-08-09	Donnell Michael A O	Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen
AU2001261585B2 (en)	2000-05-12	2006-08-31	Beth Israel Deaconess Medical Center, Inc.	Compositions and methods for achieving immune suppression
EP2322228B1 (en)	2000-06-05	2018-01-10	Altor BioScience Corporation	T cell receptor fusion proteins and conjugates and methods of use thereof
ES2322936T3 (es)	2000-09-14	2009-07-02	Beth Israel Deaconess Medical Center, Inc.	Modulacion de las respuestas de las celulas t mediadas por il-2 y por il-15.
US20030180888A1 (en)	2000-11-03	2003-09-25	Millennium Pharmaceuticals, Inc.	CD2000 and CD2001 molecules, and uses thereof
JP2003026599A (ja)	2001-06-11	2003-01-29	Univ Nagoya	Ｉｌ−１５遺伝子を応用したワクチンアジュバント
FI117667B (fi) *	2001-07-05	2007-01-15	Univ Zuerich	Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
WO2003080672A1 (en)	2002-03-22	2003-10-02	Aprogen, Inc.	Humanized antibody and process for preparing same
US20040156826A1 (en)	2002-09-27	2004-08-12	Fernando Dangond	Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
UA90654C2 (ru) *	2002-12-26	2010-05-25	Маунтин Вью Фармасьютикалз, Инк.	Полимерные конъюгаты интерферона-бета с повышенной биологической активностью
ZA200506724B (en)	2003-02-26	2007-03-28	Genmab As	Human antibodies specific for interleukin 15 (IL-15)
DE10324708A1 (de)	2003-05-30	2004-12-16	Ltn Servotechnik Gmbh	Schleifringelement und Verfahren zu dessen Herstellung
CN1233822C (zh)	2003-09-05	2005-12-28	中国科学技术大学	白细胞介素－15基因修饰的自然杀伤细胞株及其制备方法
CN1901839A (zh)	2003-11-10	2007-01-24	阿尔特生物科学公司	可溶性tcr分子及其用途
WO2005085282A1 (en)	2004-02-27	2005-09-15	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity
EP1586585A1 (de)	2004-04-14	2005-10-19	F. Hoffmann-La Roche Ag	Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
CN100334112C (zh)	2004-10-15	2007-08-29	上海海欣生物技术有限公司	人白细胞介素15与Fc融合蛋白
ES2601896T3 (es)	2004-11-24	2017-02-16	Fred Hutchinson Cancer Research Center	Procedimientos de uso de la IL-21 en la inmunoterapia adoptiva y la identificación de antígenos tumorales
MX2007006832A (es)	2004-12-13	2007-08-07	Cytos Biotechnology Ag	Arreglos de antigeno interleucina 15 y usos de los mismos.
AU2011203119C1 (en) *	2005-05-09	2018-06-14	E. R. Squibb & Sons, L.L.C.	Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
PL1899364T5 (pl)	2005-05-17	2024-12-09	University Of Connecticut	Kompozycje i sposoby immunomodulacji w organizmie
KR20070000252A (ko)	2005-06-27	2007-01-02	삼성에스디아이 주식회사	연료 전지용 전극 및 이를 포함하는 연료 전지 시스템
EP1777294A1 (en)	2005-10-20	2007-04-25	Institut National De La Sante Et De La Recherche Medicale (Inserm)	IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
ES2352561T3 (es)	2006-06-30	2011-02-21	Conaris Research Institute Ag	Dímeros de sgp 130fc mejorados.
US7965180B2 (en)	2006-09-28	2011-06-21	Semiconductor Energy Laboratory Co., Ltd.	Wireless sensor device
ES2529166T3 (es)	2007-03-30	2015-02-17	Memorial Sloan-Kettering Cancer Center	Expresión constitutiva de ligandos coestimuladores en linfocitos T transferidos de forma adoptiva
ES2470772T3 (es)	2007-05-11	2014-06-24	Altor Bioscience Corporation	Moléculas de fusión y variantes de IL-15
AU2013273643C1 (en)	2007-05-11	2016-08-11	Altor Bioscience Corporation	Fusion molecules and il-15 variants
EP2167528B1 (en)	2007-06-21	2018-01-10	Angelica Therapeutics, INC.	Modified toxins
ES2716476T3 (es)	2007-06-27	2019-06-12	Us Health	Complejos de IL15 e IL15Ralfa y sus usos
US20110070191A1 (en)	2008-03-19	2011-03-24	Wong Hing C	T cell receptor fusions and conjugates and methods of use there of
ES2363358B1 (es) *	2009-04-03	2012-06-21	FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al	Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
CN103370339B (zh)	2010-09-21	2017-12-26	阿尔托生物科学有限公司	多聚体il‑15可溶性融合分子与其制造与使用方法
US11053299B2 (en)	2010-09-21	2021-07-06	Immunity Bio, Inc.	Superkine
EP2670847B1 (en) *	2011-02-03	2016-10-05	XOMA Technology Ltd.	Methods and materials for enhancing functional protein expression in bacteria
EP2537933A1 (en)	2011-06-24	2012-12-26	Institut National de la Santé et de la Recherche Médicale (INSERM)	An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US20130302274A1 (en) *	2011-11-25	2013-11-14	Roche Glycart Ag	Combination therapy
US9682143B2 (en) *	2012-08-14	2017-06-20	Ibc Pharmaceuticals, Inc.	Combination therapy for inducing immune response to disease
WO2014028776A1 (en) *	2012-08-15	2014-02-20	Zyngenia, Inc.	Monovalent and multivalent multispecific complexes and uses thereof
MX365527B (es) *	2012-10-24	2019-06-06	Us Health	Formas il-15r alfa, celulas que expresan las formas de il-15 alfa, y usos terapeuticos de il-15r alfa y complejos il-15/il-15r.
ES2828982T3 (es) *	2013-05-14	2021-05-28	Univ Texas	Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas
PT3094351T (pt)	2014-01-15	2022-02-22	Kadmon Corp Llc	Agentes imunomoduladores
KR102398246B1 (ko)	2014-06-30	2022-05-17	알토 바이오사이언스 코포레이션	Il-15-베이즈드 분자 및 이의 사용 방법
CN104672325A (zh)	2015-03-11	2015-06-03	福建农林大学	一种用新鲜螺旋藻制备藻蓝蛋白的方法
CA2999294A1 (en)	2015-09-25	2017-03-30	Altor Bioscience Corporation	Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
WO2017205726A1 (en)	2016-05-27	2017-11-30	Altor Bioscience Corporation	Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
US20180200366A1 (en)	2016-10-21	2018-07-19	Altor Bioscience Corporation	Multimeric il-15-based molecules
CN111867612B (zh)	2018-03-26	2024-11-12	阿尔托生物科学有限责任公司	抗PDL1、IL-15和TGF-β受体组合分子

2015
- 2015-06-30 KR KR1020177002560A patent/KR102398246B1/ko active Active
- 2015-06-30 KR KR1020217022404A patent/KR102503476B1/ko active Active
- 2015-06-30 CN CN202011477829.2A patent/CN112494646A/zh active Pending
- 2015-06-30 ES ES15815782T patent/ES2899890T3/es active Active
- 2015-06-30 EP EP15815782.6A patent/EP3160498B1/en active Active
- 2015-06-30 KR KR1020257002250A patent/KR20250020700A/ko active Pending
- 2015-06-30 EP EP21173707.7A patent/EP3912637A1/en active Pending
- 2015-06-30 CA CA3151221A patent/CA3151221A1/en active Pending
- 2015-06-30 PL PL15815782T patent/PL3160498T3/pl unknown
- 2015-06-30 CN CN201580046144.3A patent/CN106659775B/zh active Active
- 2015-06-30 KR KR1020237005025A patent/KR102762243B1/ko active Active
- 2015-06-30 EP EP20152694.4A patent/EP3673915A1/en active Pending
- 2015-06-30 CA CA2953816A patent/CA2953816C/en active Active
- 2015-06-30 MX MX2017000116A patent/MX387159B/es unknown
- 2015-06-30 JP JP2016575844A patent/JP6842926B2/ja active Active
- 2015-06-30 AU AU2015284248A patent/AU2015284248B2/en active Active
- 2015-06-30 US US14/755,989 patent/US9925247B2/en active Active
- 2015-06-30 WO PCT/US2015/038587 patent/WO2016004060A2/en not_active Ceased
- 2015-06-30 CN CN202110724454.3A patent/CN113384686B/zh active Active
2018
- 2018-03-14 US US15/921,512 patent/US10537615B2/en active Active
2019
- 2019-06-18 US US16/444,807 patent/US11173191B2/en active Active
2020
- 2020-04-23 JP JP2020076412A patent/JP2020128390A/ja not_active Withdrawn
- 2020-07-01 AU AU2020204408A patent/AU2020204408B2/en active Active
- 2020-07-09 US US16/925,138 patent/US11471511B2/en active Active
2021
- 2021-07-21 JP JP2021120881A patent/JP2021176880A/ja active Pending
2022
- 2022-03-14 AU AU2022201758A patent/AU2022201758B2/en active Active
- 2022-05-26 US US17/825,959 patent/US11679144B2/en active Active
- 2022-10-11 US US18/045,572 patent/US11992516B2/en active Active
- 2022-12-09 US US18/063,871 patent/US11890323B2/en active Active
2023
- 2023-02-27 US US18/175,112 patent/US11925676B2/en active Active
- 2023-02-28 US US18/176,196 patent/US12186372B2/en active Active
- 2023-03-10 JP JP2023037991A patent/JP7561905B2/ja active Active
- 2023-12-22 US US18/394,409 patent/US12097244B2/en active Active
2024
- 2024-04-18 US US18/639,678 patent/US12268731B2/en active Active
- 2024-04-18 US US18/639,659 patent/US20240261373A1/en active Pending
- 2024-05-30 US US18/678,987 patent/US20240299498A1/en not_active Abandoned
- 2024-06-07 US US18/737,455 patent/US12268732B2/en active Active
- 2024-06-07 US US18/737,465 patent/US12318432B2/en active Active
- 2024-07-18 AU AU2024204957A patent/AU2024204957A1/en active Pending
- 2024-09-18 JP JP2024161452A patent/JP2025000709A/ja active Pending
2025
- 2025-04-30 US US19/195,326 patent/US20250262278A1/en active Pending
- 2025-04-30 US US19/195,307 patent/US20250262277A1/en active Pending

Also Published As

Publication number	Publication date
EP3912637A1 (en)	2021-11-24
US11471511B2 (en)	2022-10-18
CA3151221A1 (en)	2016-01-07
US20240261373A1 (en)	2024-08-08
US10537615B2 (en)	2020-01-21
US20230190877A1 (en)	2023-06-22
WO2016004060A3 (en)	2016-03-17
MX2017000116A (es)	2017-05-30
US9925247B2 (en)	2018-03-27
US12268732B2 (en)	2025-04-08
WO2016004060A9 (en)	2016-04-14
KR20170047221A (ko)	2017-05-04
US20210030844A1 (en)	2021-02-04
US20240307495A1 (en)	2024-09-19
US20200016239A1 (en)	2020-01-16
US20250262278A1 (en)	2025-08-21
JP2023081999A (ja)	2023-06-13
US11992516B2 (en)	2024-05-28
AU2020204408B2 (en)	2022-03-24
EP3673915A1 (en)	2020-07-01
US20230241174A1 (en)	2023-08-03
CN106659775B (zh)	2021-08-06
US12268731B2 (en)	2025-04-08
AU2022201758B2 (en)	2024-07-18
ES2899890T3 (es)	2022-03-15
KR102398246B1 (ko)	2022-05-17
JP2020128390A (ja)	2020-08-27
EP3160498A4 (en)	2017-12-06
JP2021176880A (ja)	2021-11-11
US11925676B2 (en)	2024-03-12
KR102762243B1 (ko)	2025-02-05
AU2024204957A1 (en)	2024-08-08
AU2022201758A1 (en)	2022-04-07
US20240252591A1 (en)	2024-08-01
AU2015284248B2 (en)	2020-04-16
JP2017521410A (ja)	2017-08-03
US20240131115A1 (en)	2024-04-25
US20250262277A1 (en)	2025-08-21
US20150374790A1 (en)	2015-12-31
KR20210092338A (ko)	2021-07-23
CN113384686B (zh)	2024-11-01
US11173191B2 (en)	2021-11-16
CN112494646A (zh)	2021-03-16
WO2016004060A2 (en)	2016-01-07
US20240307494A1 (en)	2024-09-19
EP3160498A2 (en)	2017-05-03
US20240299498A1 (en)	2024-09-12
AU2020204408A1 (en)	2020-07-23
JP2025000709A (ja)	2025-01-07
CA2953816A1 (en)	2016-01-07
CN106659775A (zh)	2017-05-10
US20230241175A1 (en)	2023-08-03
US20220305087A1 (en)	2022-09-29
KR102503476B1 (ko)	2023-02-24
US11890323B2 (en)	2024-02-06
US12097244B2 (en)	2024-09-24
KR20250020700A (ko)	2025-02-11
US12318432B2 (en)	2025-06-03
AU2015284248A1 (en)	2017-01-12
CN113384686A (zh)	2021-09-14
US20230233649A1 (en)	2023-07-27
EP3160498B1 (en)	2021-10-06
US11679144B2 (en)	2023-06-20
MX387159B (es)	2025-03-18
JP7561905B2 (ja)	2024-10-04
CA2953816C (en)	2022-03-15
KR20230028807A (ko)	2023-03-02
US12186372B2 (en)	2025-01-07
JP6842926B2 (ja)	2021-03-17
US20190022187A1 (en)	2019-01-24

Publication	Publication Date	Title
PL3160498T3 (pl)	2022-02-21	Cząsteczki na bazie IL-15 i sposoby ich zastosowania
FIC20230014I1 (fi)	2023-03-31	Foslevodopa ja foskarbidopa
IL251970B (en)	2021-12-01	Anti-cd79b antibodies and methods of use
IL282048A (en)	2021-05-31	Oxysterols and methods of use thereof
PL3353210T3 (pl)	2025-02-24	Przeciwciała anty-TIGIT i sposoby stosowania
IL249092A0 (en)	2017-01-31	Anti-gitr antibodies and methods of use thereof
PL3250610T3 (pl)	2024-01-29	Przeciwciała anty-FcRn i sposoby ich stosowania
HUE052373T2 (hu)	2021-04-28	Szubsztituált krománok és alkalmazási eljárások
KR20180084817A (ko)	2018-07-25	항-siglec-9 항체 및 이의 이용 방법
EP4212536C0 (en)	2025-02-19	BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
HUE049032T2 (hu)	2020-08-28	PVRIG elleni antitestek és alkalmazási eljárások
DK3215532T3 (da)	2020-01-02	Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3169704T3 (da)	2020-10-26	Molekyler med specificitet for cd45 og cd79
PL3828194T3 (pl)	2025-09-22	Oksysterole i sposoby ich stosowania
DK3331876T3 (da)	2021-01-11	Modulators of ror-gamma
MA40933A (fr)	2017-09-19	Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
IL251988A0 (en)	2017-06-29	Glycan-interacting compounds and methods of use
BR112017004648A2 (pt)	2018-05-08	simuladores mir-29 e os usos deste
HRP20170840T1 (hr)	2017-09-08	Supstituirani ksantini i metode njihove uporabe
PL3288553T3 (pl)	2023-03-20	Połączenia kannabinoidów i n-acyloetanoloamin
IL251505A0 (en)	2017-05-29	Neuroactive compounds and methods of use thereof
HUE059701T2 (hu)	2022-12-28	Antitestek és felhasználási módszerek
EP3152293C0 (en)	2025-07-30	PERFUSION CULTURE METHODS AND USES THEREOF
EP3879472C0 (en)	2025-05-07	COMPARISON AND SIMULATION OF WASHES FOR CIP
BR112016024803A2 (pt)	2018-06-19	suportes abrasivos e métodos de sua formação